A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Read more about A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Read more about Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Read more about Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Read more about Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Read more about Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients. Read more about Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Read more about A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Read more about Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease. Read more about A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.
Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. Read more about Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis.
